Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jerini AG

Division of Takeda Pharmaceutical Co. Ltd.
www.jerini.com

Latest From Jerini AG

Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead

Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.

Business Strategies Growth

Orphans Should Live Alone

For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.

BioPharmaceutical Strategy

Shire faces RoI test under vision-loving new CEO

Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.

Gastrointestinal

Stockwatch: Which way is up?

As the third quarter earnings season starts to trail off, investors could be forgiven for wondering what it takes anymore for the share prices of companies to go up, rather than down. Over the past two weeks, the delineation between big pharmaceutical companies and big biotechnology companies couldn't have been clearer with big biotechs like Amgen, Gilead, Celgene and Biogen reporting better than expected quarterly profits and raising guidance, whereas big pharmas like Pfizer, Lilly, GlaxoSmithKline and Bristol Myers Squibb all drifted in the shadow of their respective patent expiries (scripintelligence.com, 25 October 2012).

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Jens Schneider-Mergener, PhD, CEO
    Berndt Modig, CFO
    Christiane Hanke-Harloff, PhD, VP, Sales & Mktg.
    Jochen Knolle, CSO
  • Contact Info
  • Jerini AG
    Phone: (49) 30-978 93-0
    Invalidenstr. 130
    Berlin, 10115
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register